The New York Times profiles GlaxoSmithKline's Andrew Witty, particularly focusing on his efforts to help the poor. Witty has promised to limit the price of GSK drugs in poor countries to no more than 25 percent of what they charge in wealthy nations and to donate one-fifth of the profits from poor countries to build up their healthcare systems. Witty, of course, has his detractors.
Get the full story
This story is free
for registered users
Registering provides access to this and other free content.
Register now.Already have an account?
Login Now.